You are here

P&T® Journal contents for August 2010

Features

A Retrospective Analysis of a Large Managed Care Claims Database
Although selective serotonin reuptake inhibitors (SSRIs) are considered cost-effective for major depression, dosage adjustments may be necessary when therapy starts. In the authors' study, patients undergoing dose titration of SSRIs used more medical resources and spent more days receiving a subtherapeutic dose than comparable controls not undergoing dose titration.
Fabian Camacho, MS, MA; Meg C. Kong, PhD; David V. Sheehan, MD, MBA; and Rajesh Balkrishnan, PhD
The Widespread Use of CAM and the Need for Better-Informed Health Care Professionals to Provide Patient Counseling
Pharmacists and physicians are in an ideal position to counsel patients on the use of dietary supplements and CAM, but many currently lack the formal training needed to help the growing number of people who wish to use these treatments. Standards have been issued to guide health care professionals, but more initiatives are needed.
C. Lee Ventola, MS
Meeting Highlights
Topics include medications for chronic myelogenous leukemia, melanoma, multiple myeloma, breast cancer, renal cell carcinoma, and lung cancer. The centuries-old history of rose bengal, a promising agent for melanoma, is also presented.
Walter Alexander
Cabazitaxel (Jevtana) injection for hormone-refractory prostate cancer, aztreonam inhalation solution (Cayston) for improving respiratory symptoms in cystic fibrosis, and denosumab (Prolia) for postmenopausal women with osteoporosis are discussed.
Marvin M. Goldenberg, PhD, RPh, MS

Departments

Editorial
A new report ranks the health of each county in the U.S., with an emphasis on quality-of-care measures designed to improve the overall health of residents.
David B. Nash, MD, MBA
Medication Errors
Unlabeled Syringes Are Surprisingly Common
Reducing errors involving injectable drugs can be accomplished if syringes are labeled appropriately.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
A new law requiring insurance coverage for mental health and substance abuse might force companies to reduce hospital and drug benefits for their employees.
Stephen Barlas
FDA approvals, drug indications, product recalls, and industry updates
Drug Forecast
Guanfacine extended-release (Intuniv) tablets, a nonstimulant agent for attention/deficit hyperactivity disorder in children and adolescents
Martin P. Cruz, PharmD, CGP, BCPP